Karyopharm Therapeut (KPTI)

$4.54 +0.15 (3.42%)
Market Cap 37.93M
Revenue (ttm) 145.24M
Net Income (ttm) -76.42M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -52.62%
Debt to Equity Ratio -0.58
Volume 27,300
Avg Vol 89,472
Day's Range N/A - N/A
Shares Out 8.64M
Stochastic %K 66%
Beta 0.23
Analysts Strong Sell
Price Target $33.07

Company Profile

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for th...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 658 0600
Address:
85 Wells Avenue, 2nd Floor, Suite 210, Newton, United States
Kevin73ca
Kevin73ca Jun. 16 at 12:35 AM
$JFBR $KPTI $NVCR $PPBT What’s that meaning
0 · Reply
BiotechBonesaw
BiotechBonesaw Jun. 15 at 6:40 PM
$JFBR rumor is they’re going after short sellers of their companies next 🤯 $KPTI $NVCR $PPBT
1 · Reply
DoctorDueDiligence
DoctorDueDiligence Jun. 10 at 2:09 PM
$KPTI why do you think the Board chose not to act? Despite knowing runway was short of 3 3 Trial readouts? https://x.com/duedoctor/status/1932423855626461647?s=46
0 · Reply
DoctorDueDiligence
DoctorDueDiligence Jun. 10 at 9:27 AM
$KPTI Dr. DD's Thoughts on MF, comparing to MorphoSys, board etc https://x.com/duedoctor/status/1932351590293217505?s=46
0 · Reply
BiotechBonesaw
BiotechBonesaw Jun. 6 at 9:18 PM
$NUVB $NUVL I wish @Stocktwits had a polling feature so we could answer questions like this! 🧐 It would be interesting to track. 🤷‍♂️ Good luck to both companies, $PPBT , $KPTI , and all the undervalued biotechs fighting cancer ♋️
0 · Reply
celebratelife
celebratelife Jun. 5 at 8:56 PM
$KPTI Party Paulson Today
0 · Reply
celebratelife
celebratelife Jun. 5 at 8:50 PM
$KPTI Hard to believe this chap https://x.com/karyowatch/status/1930728675051184340
0 · Reply
steven1x
steven1x Jun. 5 at 8:24 PM
$KPTI jeffries
3 · Reply
celebratelife
celebratelife Jun. 5 at 4:52 PM
$KPTI https://www.youtube.com/watch?v=2ch8xaAfMpo
0 · Reply
celebratelife
celebratelife Jun. 5 at 3:32 PM
$KPTI Moronic Mismanagement Not Misfortune https://x.com/karyowatch/status/1930648813343003063
0 · Reply
Latest News on KPTI
Karyopharm to Present at the Jefferies Global Healthcare Conference

Jun 3, 2025, 8:00 AM EDT - 13 days ago

Karyopharm to Present at the Jefferies Global Healthcare Conference

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jun 2, 2025, 4:05 PM EDT - 14 days ago

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Karyopharm to Participate at the 2025 RBC Capital Markets Global Healthcare Conference

May 19, 2025, 7:00 AM EDT - 4 weeks ago

Karyopharm to Participate at the 2025 RBC Capital Markets Global Healthcare Conference

Karyopharm Announces Poster Presentation on Selinexor in Myelofibrosis at the 2025 European Hematology Association Annual Meeting

May 14, 2025, 9:31 AM EDT - 4 weeks ago

Karyopharm Announces Poster Presentation on Selinexor in Myelofibrosis at the 2025 European Hematology Association Annual Meeting

These Analysts Revise Their Forecasts On Karyopharm Therapeutics After Q1 Results

May 13, 2025, 1:39 PM EDT - 4 weeks ago

These Analysts Revise Their Forecasts On Karyopharm Therapeutics After Q1 Results

Karyopharm Therapeutics Inc. (KPTI) Q1 2025 Earnings Call Transcript

May 13, 2025, 7:15 AM EDT - 4 weeks ago

Karyopharm Therapeutics Inc. (KPTI) Q1 2025 Earnings Call Transcript

Karyopharm Reports First Quarter 2025 Financial Results and Announces New Data in Myelofibrosis that Further Suggests Selinexor May Lead to Meaningful Spleen Volume Reduction, Symptom Improvement, Hemoglobin Stabilization and Disease Modification

May 12, 2025, 4:05 PM EDT - 5 weeks ago

Karyopharm Reports First Quarter 2025 Financial Results and Announces New Data in Myelofibrosis that Further Suggests Selinexor May Lead to Meaningful Spleen Volume Reduction, Symptom Improvement, Hemoglobin Stabilization and Disease Modification

Karyopharm to Report First Quarter 2025 Financial Results on May 12, 2025

May 8, 2025, 4:05 PM EDT - 5 weeks ago

Karyopharm to Report First Quarter 2025 Financial Results on May 12, 2025

XPOVIO® (selinexor) Approved for Commercialization in Indonesia, Further Expanding Antengene's Commercial Presence in APAC

Mar 5, 2025, 12:00 AM EST - 3 months ago

XPOVIO® (selinexor) Approved for Commercialization in Indonesia, Further Expanding Antengene's Commercial Presence in APAC

Karyopharm Announces 1-for-15 Reverse Stock Split

Feb 24, 2025, 8:40 AM EST - 4 months ago

Karyopharm Announces 1-for-15 Reverse Stock Split

Karyopharm Therapeutics Inc. (KPTI) Q4 2024 Earnings Call Transcript

Feb 19, 2025, 11:05 AM EST - 4 months ago

Karyopharm Therapeutics Inc. (KPTI) Q4 2024 Earnings Call Transcript

Karyopharm Reports Fourth Quarter and Full Year 2024 Financial Results, Announces Update to Phase 3 XPORT-EC-042 Trial and Highlights Recent Company Progress

Feb 19, 2025, 7:30 AM EST - 4 months ago

Karyopharm Reports Fourth Quarter and Full Year 2024 Financial Results, Announces Update to Phase 3 XPORT-EC-042 Trial and Highlights Recent Company Progress

Antengene Announces XPOVIO® Approved for Public Health Insurance Coverage in Taiwan Market, Benefiting More Patients with R/R MM in the Region

Feb 13, 2025, 4:30 AM EST - 4 months ago

Antengene Announces XPOVIO® Approved for Public Health Insurance Coverage in Taiwan Market, Benefiting More Patients with R/R MM in the Region

Karyopharm to Report Fourth Quarter and Full Year 2024 Financial Results on February 19, 2025

Feb 12, 2025, 7:00 AM EST - 4 months ago

Karyopharm to Report Fourth Quarter and Full Year 2024 Financial Results on February 19, 2025

Karyopharm Announces Preliminary Unaudited 2024 Revenue and 2025 Objectives

Jan 13, 2025, 8:30 AM EST - 5 months ago

Karyopharm Announces Preliminary Unaudited 2024 Revenue and 2025 Objectives

Karyopharm Announces the Appointment of Lori Macomber as Chief Financial Officer

Jan 2, 2025, 7:00 AM EST - 5 months ago

Karyopharm Announces the Appointment of Lori Macomber as Chief Financial Officer

Karyopharm Announces the Appointment of Brendan Strong as Senior Vice President of Investor Relations and Corporate Communications

Dec 9, 2024, 8:00 AM EST - 6 months ago

Karyopharm Announces the Appointment of Brendan Strong as Senior Vice President of Investor Relations and Corporate Communications

Karyopharm Therapeutics Provides Endometrial Cancer Program Update

Dec 3, 2024, 7:00 AM EST - 6 months ago

Karyopharm Therapeutics Provides Endometrial Cancer Program Update

Karyopharm to Participate at the Piper Sandler 36th Annual Healthcare Conference

Nov 25, 2024, 7:00 AM EST - 7 months ago

Karyopharm to Participate at the Piper Sandler 36th Annual Healthcare Conference

Karyopharm Therapeutics Announces the Appointment of Chief Accounting Officer

Nov 20, 2024, 4:05 PM EST - 7 months ago

Karyopharm Therapeutics Announces the Appointment of Chief Accounting Officer

Karyopharm to Present Selinexor Data at the 66th American Society of Hematology Annual Meeting and Exposition

Nov 18, 2024, 7:00 AM EST - 7 months ago

Karyopharm to Present Selinexor Data at the 66th American Society of Hematology Annual Meeting and Exposition

Karyopharm Therapeutics Inc. (KPTI) Q3 2024 Earnings Call Transcript

Nov 5, 2024, 9:22 PM EST - 7 months ago

Karyopharm Therapeutics Inc. (KPTI) Q3 2024 Earnings Call Transcript

Antengene to Present Results from Two Late-Stage Studies of Selinexor Signaling Potential Clinical Breakthrough at ASH 2024

Nov 5, 2024, 7:30 PM EST - 7 months ago

Antengene to Present Results from Two Late-Stage Studies of Selinexor Signaling Potential Clinical Breakthrough at ASH 2024

Karyopharm Reports Third Quarter 2024 Financial Results and Highlights Recent Company Progress

Nov 5, 2024, 7:30 AM EST - 7 months ago

Karyopharm Reports Third Quarter 2024 Financial Results and Highlights Recent Company Progress

Karyopharm to Report Third Quarter 2024 Financial Results on November 5, 2024

Oct 31, 2024, 8:00 AM EDT - 8 months ago

Karyopharm to Report Third Quarter 2024 Financial Results on November 5, 2024

Karyopharm Announces Favorable Change in Co-Primary Endpoint for Pivotal Phase 3 SENTRY Trial in Myelofibrosis

Oct 31, 2024, 7:30 AM EDT - 8 months ago

Karyopharm Announces Favorable Change in Co-Primary Endpoint for Pivotal Phase 3 SENTRY Trial in Myelofibrosis

Karyopharm to Host Investor Event with Leading Myelofibrosis KOLs and Provide a Favorable Study Design Update on October 31, 2024

Oct 30, 2024, 4:30 PM EDT - 8 months ago

Karyopharm to Host Investor Event with Leading Myelofibrosis KOLs and Provide a Favorable Study Design Update on October 31, 2024

Antengene Announces XPOVIO® (selinexor) Approved for Its Third Indication in South Korea, Bringing Fresh Hope to Patients with MM in the Country

Oct 17, 2024, 10:35 PM EDT - 8 months ago

Antengene Announces XPOVIO® (selinexor) Approved for Its Third Indication in South Korea, Bringing Fresh Hope to Patients with MM in the Country

Antengene Announces XPOVIO® (selinexor) Approved for Commercialization in Thailand

Sep 23, 2024, 5:00 AM EDT - 9 months ago

Antengene Announces XPOVIO® (selinexor) Approved for Commercialization in Thailand

Karyopharm to Participate at Upcoming Investor Conferences

Sep 3, 2024, 7:00 AM EDT - 10 months ago

Karyopharm to Participate at Upcoming Investor Conferences

Karyopharm Reports Second Quarter 2024 Financial Results and Highlights Recent Company Progress

Aug 6, 2024, 7:30 AM EDT - 11 months ago

Karyopharm Reports Second Quarter 2024 Financial Results and Highlights Recent Company Progress

Antengene Announces XPOVIO® (selinexor) Approved for Commercialization in Malaysia

Aug 5, 2024, 8:00 PM EDT - 11 months ago

Antengene Announces XPOVIO® (selinexor) Approved for Commercialization in Malaysia

Karyopharm to Report Second Quarter 2024 Financial Results on August 6, 2024

Jul 31, 2024, 4:05 PM EDT - 11 months ago

Karyopharm to Report Second Quarter 2024 Financial Results on August 6, 2024

XPOVIO® (selinexor) Approved for New Indication in DLBCL in China, Bringing a New Treatment Option to Patients in the Country

Jul 5, 2024, 9:10 AM EDT - 1 year ago

XPOVIO® (selinexor) Approved for New Indication in DLBCL in China, Bringing a New Treatment Option to Patients in the Country

Antengene Announces XPOVIO® (selinexor) National Health Insurance Service Approval for Reimbursement in South Korea

Jun 26, 2024, 4:42 AM EDT - 1 year ago

Antengene Announces XPOVIO® (selinexor) National Health Insurance Service Approval for Reimbursement in South Korea

Karyopharm Presents Updated Exploratory Subgroup Analyses from SIENDO Study in Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer During 2024 ASCO Plenary Series: Rapid Abstract Updates

Jun 1, 2024, 1:45 PM EDT - 1 year ago

Karyopharm Presents Updated Exploratory Subgroup Analyses from SIENDO Study in Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer During 2024 ASCO Plenary Series: Rapid Abstract Updates

Karyopharm to Participate at the Jefferies Global Healthcare Conference

May 29, 2024, 4:05 PM EDT - 1 year ago

Karyopharm to Participate at the Jefferies Global Healthcare Conference

Karyopharm to Participate at the 2024 RBC Capital Markets Global Healthcare Conference

May 8, 2024, 4:05 PM EDT - 1 year ago

Karyopharm to Participate at the 2024 RBC Capital Markets Global Healthcare Conference

Karyopharm Therapeutics Inc. (KPTI) Q1 2024 Earnings Call Transcript

May 8, 2024, 3:38 PM EDT - 1 year ago

Karyopharm Therapeutics Inc. (KPTI) Q1 2024 Earnings Call Transcript

Karyopharm Announces Significant Refinancing Transactions and Amended Royalty Agreement Extending Vast Majority of Its Debt Maturities into 2028 and 2029

May 8, 2024, 7:30 AM EDT - 1 year ago

Karyopharm Announces Significant Refinancing Transactions and Amended Royalty Agreement Extending Vast Majority of Its Debt Maturities into 2028 and 2029

Karyopharm Reports First Quarter 2024 Financial Results and Highlights Recent Company Progress

May 8, 2024, 7:30 AM EDT - 1 year ago

Karyopharm Reports First Quarter 2024 Financial Results and Highlights Recent Company Progress

Karyopharm to Report First Quarter 2024 Financial Results on May 8, 2024

May 2, 2024, 4:30 PM EDT - 1 year ago

Karyopharm to Report First Quarter 2024 Financial Results on May 8, 2024

Karyopharm Therapeutics: Spiraling Despite Upcoming Catalysts

Apr 30, 2024, 2:28 PM EDT - 1 year ago

Karyopharm Therapeutics: Spiraling Despite Upcoming Catalysts

Karyopharm Announces Presentations in Endometrial Cancer and Myelofibrosis at the 2024 American Society of Clinical Oncology Annual Meeting

Apr 24, 2024, 4:01 PM EDT - 1 year ago

Karyopharm Announces Presentations in Endometrial Cancer and Myelofibrosis at the 2024 American Society of Clinical Oncology Annual Meeting

Karyopharm to Participate at Barclays 26th Annual Global Healthcare and Leerink Partners Global Biopharma Conferences

Mar 6, 2024, 4:05 PM EST - 1 year ago

Karyopharm to Participate at Barclays 26th Annual Global Healthcare and Leerink Partners Global Biopharma Conferences

Karyopharm Therapeutics Inc. (KPTI) Q4 2023 Earnings Call Transcript

Feb 29, 2024, 11:26 AM EST - 1 year ago

Karyopharm Therapeutics Inc. (KPTI) Q4 2023 Earnings Call Transcript

Karyopharm Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Company Progress

Feb 29, 2024, 7:30 AM EST - 1 year ago

Karyopharm Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Company Progress

Karyopharm to Report Fourth Quarter and Full Year 2023 Financial Results on February 29, 2024

Feb 22, 2024, 7:00 AM EST - 1 year ago

Karyopharm to Report Fourth Quarter and Full Year 2023 Financial Results on February 29, 2024

Karyopharm: Approaching The Bottom Ahead Of Earnings And Topline Data (Rating Upgrade)

Feb 5, 2024, 12:26 PM EST - 1 year ago

Karyopharm: Approaching The Bottom Ahead Of Earnings And Topline Data (Rating Upgrade)

Karyopharm Announces Preliminary Unaudited 2023 Revenue and 2024 Objectives

Jan 8, 2024, 8:30 AM EST - 1 year ago

Karyopharm Announces Preliminary Unaudited 2023 Revenue and 2024 Objectives

Kevin73ca
Kevin73ca Jun. 16 at 12:35 AM
$JFBR $KPTI $NVCR $PPBT What’s that meaning
0 · Reply
BiotechBonesaw
BiotechBonesaw Jun. 15 at 6:40 PM
$JFBR rumor is they’re going after short sellers of their companies next 🤯 $KPTI $NVCR $PPBT
1 · Reply
DoctorDueDiligence
DoctorDueDiligence Jun. 10 at 2:09 PM
$KPTI why do you think the Board chose not to act? Despite knowing runway was short of 3 3 Trial readouts? https://x.com/duedoctor/status/1932423855626461647?s=46
0 · Reply
DoctorDueDiligence
DoctorDueDiligence Jun. 10 at 9:27 AM
$KPTI Dr. DD's Thoughts on MF, comparing to MorphoSys, board etc https://x.com/duedoctor/status/1932351590293217505?s=46
0 · Reply
BiotechBonesaw
BiotechBonesaw Jun. 6 at 9:18 PM
$NUVB $NUVL I wish @Stocktwits had a polling feature so we could answer questions like this! 🧐 It would be interesting to track. 🤷‍♂️ Good luck to both companies, $PPBT , $KPTI , and all the undervalued biotechs fighting cancer ♋️
0 · Reply
celebratelife
celebratelife Jun. 5 at 8:56 PM
$KPTI Party Paulson Today
0 · Reply
celebratelife
celebratelife Jun. 5 at 8:50 PM
$KPTI Hard to believe this chap https://x.com/karyowatch/status/1930728675051184340
0 · Reply
steven1x
steven1x Jun. 5 at 8:24 PM
$KPTI jeffries
3 · Reply
celebratelife
celebratelife Jun. 5 at 4:52 PM
$KPTI https://www.youtube.com/watch?v=2ch8xaAfMpo
0 · Reply
celebratelife
celebratelife Jun. 5 at 3:32 PM
$KPTI Moronic Mismanagement Not Misfortune https://x.com/karyowatch/status/1930648813343003063
0 · Reply
celebratelife
celebratelife Jun. 4 at 4:52 PM
$KPTI Richard Paulson, Barry Greene, Mike Mano et al. are destroyers of our money and dream come true for shorts. Competent CEOs act differently: https://x.com/karyowatch/status/1930306265122779535
0 · Reply
celebratelife
celebratelife Jun. 4 at 5:32 AM
$KPTI Hedge fund cockroaches https://x.com/karyowatch/status/1930135245874933933
0 · Reply
celebratelife
celebratelife Jun. 3 at 5:14 PM
$KPTI NEW LETTER TO THE BOARD ABOUT LIABILITY https://x.com/karyowatch/status/1929949673357283349
0 · Reply
AZOZ
AZOZ Jun. 3 at 2:19 PM
$KPTI on watch for possible reversal!
0 · Reply
celebratelife
celebratelife Jun. 2 at 8:20 PM
$KPTI Shorts got Paulson et al. by the balls and... https://x.com/karyowatch/status/1929633592663331221
0 · Reply
celebratelife
celebratelife Jun. 1 at 11:01 PM
$KPTI FIRING RICHARD PAULSON IS URGENTLY NEEDED: https://x.com/karyowatch/status/1929312282468614530
0 · Reply
celebratelife
celebratelife Jun. 1 at 5:09 PM
$KPTI hard to believe Paulson : https://x.com/karyowatch/status/1929223532371730881
0 · Reply
celebratelife
celebratelife May. 30 at 10:03 PM
$KPTI ABSOLUTELY URGENT NOTICE TO KARYOPHARM BOARD REQUIRING URGENT ACTION. Link to letter to the Board is here: https://x.com/karyowatch/status/1928572495008866432
0 · Reply
celebratelife
celebratelife May. 30 at 8:38 PM
$KPTI ABOUT THE INCOMPETENT SELF SERVING ASSET DESTROYERS https://x.com/karyowatch/status/1928551209905860993
0 · Reply
nacho217
nacho217 May. 30 at 1:45 PM
$KPTI This company is a fucking scam and those responsible should pay for it.
0 · Reply
celebratelife
celebratelife May. 29 at 12:15 AM
$KPTI URGENT MESSAGE TO BARRY GREENE https://x.com/karyowatch/status/1927881332920668237
0 · Reply
celebratelife
celebratelife May. 28 at 9:37 PM
$KPTI Why Paulson must get fired: https://x.com/karyowatch/status/1927840915697115279
0 · Reply